Get the Stockscreener App
9.77
0.31%
-0.03
Lexeo Therapeutics Inc stock is traded at $9.77, with a volume of 661.52K.
It is down -0.31% in the last 24 hours and up +6.08% over the past month.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
See More
Previous Close:
$9.80
Open:
$9.78
24h Volume:
661.52K
Relative Volume:
0.54
Market Cap:
$713.09M
Revenue:
-
Net Income/Loss:
$-86.60M
P/E Ratio:
-3.4494
EPS:
-2.8324
Net Cash Flow:
$-67.37M
1W Performance:
+4.49%
1M Performance:
+6.08%
6M Performance:
+138.88%
1Y Performance:
+37.03%
1-Day Range:
$9.475
$10.02
1-Week Range:
$9.12
$10.02
52-Week Range:
$1.45
$10.38
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Name
Lexeo Therapeutics Inc
Sector
Industry
Phone
(212) 547-9879
Address
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
9.77 | 715.28M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-15-25 | Initiated | Guggenheim | Buy |
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Jun-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-28-23 | Initiated | Chardan Capital Markets | Buy |
| Nov-28-23 | Initiated | JP Morgan | Overweight |
| Nov-28-23 | Initiated | Leerink Partners | Outperform |
| Nov-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-28-23 | Initiated | Stifel | Buy |
View All
Lexeo Therapeutics Inc Stock (LXEO) Latest News
Janus Henderson Group PLC Expands Stake in Lexeo Therapeutics Inc - GuruFocus
Aug Wrap: Will Lexeo Therapeutics Inc stock benefit from AI adoptionStock Surge & Smart Allocation Stock Reports - moha.gov.vn
Lexeo Therapeutics (NASDAQ:LXEO) Receives “Buy” Rating from Chardan Capital - Defense World
Aug Action: What sentiment indicators say about Lexeo Therapeutics Inc stock - moha.gov.vn
Lexeo Therapeutics' (LXEO) Buy Rating Reaffirmed at Chardan Capital - MarketBeat
Lexeo Therapeutics (LXEO) Rating Maintained as 'Buy' by Chardan Capital | LXEO Stock News - GuruFocus
Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock By Investing.com - Investing.com Canada
Lexeo Therapeutics stock holds Overweight rating as Cantor sees PKP2-ACM potential - Investing.com Canada
Check Out Lexeo Therapeutics Inc (LXEO)’s Trade Data Rather Than the Analysts’ Views - setenews.com
Update Recap: Will Lexeo Therapeutics Inc stock benefit from AI adoptionJuly 2025 Fed Impact & Consistent Growth Equity Picks - moha.gov.vn
Portfolio Update: Why Lexeo Therapeutics Inc stock remains resilientJuly 2025 Review & Real-Time Buy Signal Notifications - moha.gov.vn
How resilient is Lexeo Therapeutics Inc. stock in market downturnsTreasury Yields & Fast Entry High Yield Stock Tips - Newser
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum - marketscreener.com
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event - GlobeNewswire
Why Lexeo Therapeutics Inc. stock remains resilientWeekly Stock Summary & Accurate Buy Signal Alerts - Newser
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Trading Down 7.8%What's Next? - MarketBeat
A look into Lexeo Therapeutics Inc (LXEO)’s deeper side - setenews.com
Lexeo Therapeutics (NASDAQ:LXEO) Now Covered by Analysts at Cantor Fitzgerald - MarketBeat
Lexeo Therapeutics stock undervalued, Cantor Fitzgerald reiterates $19 target By Investing.com - Investing.com Canada
Will Lexeo Therapeutics Inc. stock deliver shareholder valueExit Point & Consistent Income Trade Ideas - moha.gov.vn
Why Lexeo Therapeutics Inc. stock is a must watch in 2025July 2025 Patterns & Expert Approved Momentum Ideas - BỘ NỘI VỤ
Paradigm Biocapital Advisors LP Acquires Significant Stake in Le - GuruFocus
LXEO Stock Price and Chart — NASDAQ:LXEO - TradingView
Research Analysts Set Expectations for LXEO FY2025 Earnings - Defense World
Savant Capital LLC Invests $119,000 in Lexeo Therapeutics, Inc. $LXEO - MarketBeat
Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 1,127 Shares of Stock - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Coverage Initiated at Cantor Fitzgerald - MarketBeat
Adler, Lexeo Therapeutics CMO, sells $5.7k in LXEO stock By Investing.com - Investing.com Australia
Lexeo Therapeutics CEO Makes Significant Stock Sale! - TipRanks
Balyasny Asset Management L.P. Increases Stake in Lexeo Therapeu - GuruFocus
[Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity - Stock Titan
Adler, Lexeo Therapeutics CMO, sells $5.7k in LXEO stock - Investing.com
Lexeo Therapeutics CEO Sells Shares to Cover Tax Obligations - TradingView
CEO Townsend Surrenders 1,127 Of Lexeo Therapeutics Inc [LXEO] - TradingView
Cantor Fitzgerald Initiates Coverage on Lexeo Therapeutics With Overweight Rating, $19 Price Target - MarketScreener
Equities Analysts Set Expectations for LXEO FY2025 Earnings - MarketBeat
HC Wainwright Has Optimistic Outlook of LXEO FY2025 Earnings - Defense World
Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process - MSN
Real time pattern detection on Lexeo Therapeutics Inc. stockMarket Activity Recap & Precise Entry and Exit Recommendations - newser.com
Using Ichimoku Cloud for Lexeo Therapeutics Inc. technicalsWeekly Market Summary & Real-Time Volume Triggers - newser.com
Will Lexeo Therapeutics Inc. price bounce be sustainableGold Moves & Daily Entry Point Alerts - newser.com
Using data models to predict Lexeo Therapeutics Inc. stock movementQuarterly Trade Review & Reliable Entry Point Alerts - newser.com
Officer Tai Files To Sell 386 Of Lexeo Therapeutics Inc [LXEO] - TradingView
Institutional Investors Are Lexeo Therapeutics, Inc.'s (NASDAQ:LXEO) Biggest Bettors and Were Rewarded After Last Week's US$70m Market Cap Gain - 富途牛牛
Lexeo Therapeutics Insiders Benefitted From Selling Stock At US$7.01 - simplywall.st
Optimistic Buy Rating for Lexeo Therapeutics Driven by High-Dose Potential and Superior Safety Profile - TipRanks
V2Y Corporation Ltd Expands into Renewable Energy and Commodities - The Globe and Mail
Can Lexeo Therapeutics Inc. stock withstand economic slowdownWeekly Trend Summary & Stock Portfolio Risk Management - newser.com
Lexeo Therapeutics Inc Stock (LXEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexeo Therapeutics Inc Stock (LXEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Adler Eric | Chief Medical Officer |
Nov 18 '25 |
Sale |
9.27 |
615 |
5,701 |
72,646 |
| See Tai Sandi | Chief Development Officer |
Nov 18 '25 |
Sale |
9.27 |
386 |
3,578 |
65,476 |
| Robertson Jenny | Chief Legal Officer |
Nov 18 '25 |
Sale |
9.27 |
549 |
5,089 |
68,381 |
| Otero Jose Manuel | Chief Technical Officer |
Aug 18 '25 |
Sale |
9.27 |
721 |
6,684 |
63,476 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):